Eagle Pharmaceuticals Receives New Patent for Bendeka Configure

Eagle Pharmaceuticals Receives New Patent for Bendeka Configure

Source: 
CP Wire
snippet: 
  • Bendeka has Orphan Drug Exclusivity until Dec. 2022
  • Company does not expect generic entrants of previous version of Bendeka until Dec. 2022
  • Teva is responsible for all US commercial activity involving Bendeka